
    
      This is a randomized, open label, 4 way crossover Phase 1 study of the pharmacokinetics,
      safety and tolerability of a 4 mg dose of ondansetron administered subcutaneously with
      Hylenex recombinant compared to 4 mg doses of ondansetron administered intravenously and
      intramuscularly and an 8 mg dose of ondansetron administered orally.
    
  